[Erratum to BMB Reports 2010; 43(8) 554-560, PMID 20797318] The authors apologize that due to our neglect when doing the picture layout of Fig. 1A, the wrong Western blot analysis image were pasted for the "β-actin"group in the middle plot of Fig. 1A. The middle plot of Fig. 1A and its related statistics results (bottom plot in Fig.1A) have been corrected. However, the conclusions of the original article are not affected. The authors would like to apologize for any inconvenience caused.The decision of the Centers for Medicare & Medicaid Services to suspend routine surveys in favor of focused inspections targeted at infection control is the first signal that long-term care will be at the epicenter of federal oversight.To compare the impact of a pharmacist's presence for the detection of drug-related problems (DRP) in an interdisciplinary geriatric-ambulatory clinic with a control group without a pharmacist. CONCLUSION The inclusion of a pharmacist in an interdisciplinary team in an ambulatory geriatric-care clinic was associated to a positive impact on care by substantially increasing the number of DRP detected in older patients.Structural and functional degeneration of the kidneys occur as the human body ages, making oler people especially susceptible to the consequences of acute kidney injury. Furthermore, the use of nephrotoxic agents, combined with the increased incidence of acute kidney injury and likelihood of an intensive-care unit admission, makes geriatric patients prone to develop drug-induced kidney disease. Vancomycin is routinely used as the first-line treatment for methicillin-resistant Staphylococcus aureus, but is known to be nephrotoxic; studies have shown that an early switch from vancomycin to alternatives does not necessarily prevent renal insult. Therefore, we aim to discuss the mechanisms of drug-induced kidney disease with regard to vancomycin, daptomycin, and ceftaroline and to provide insight as to their safety profiles with regard to older people. A clear understanding of this topic will aid clinicians in selecting drug therapy and may lead to shortened hospital stays, lower hospital costs, and improved outcomes of critically ill older people.GERIATRIC PHARMACOTHERAPY CASE SERIES This case study reviews the treatment of a patient with overactive bladder (OAB), a geriatric syndrome that is a prevalent and multifactorial health condition associated with substantial morbidity and poor outcomes in older people. This case illustrates a counterintuitive presentation of OAB, approaches to analyzing the case, and planning for treatment.To assess changes in psychotropic pharmacotherapy for patients with dementia over a three-year period. CONCLUSION Clinically significant increases in the prescribing of anticonvulsants and sedatives suggest the possibility that these agents are used to combat behavioral and psychological symptoms of dementia in patients with dementia. Further research is required to assess the rationale, efficacy, and safety of these uses.Anxiety disorders may be the most common mental disorder among older people. Experts estimate the prevalence of anxiety to be between 1.2% and 15% in community samples and 1% and 28% in medical settings. These patients manifest the symptoms of anxiety, and they are also at risk for increased disability, decreased health-related quality of life, and possibly mild cognitive impairment. For this reason, it is important for pharmacists to understand the challenges in assessing anxiety and the treatment options that are safe and effective for older people. Additionally, pharmacists must be able to communicate well with these patients despite their tendency to perseverate and fixate.There are many opportunities for pharmacists to contribute to the better use of anxiolytic and sedative-hypnotic drugs, typically overprescribed and maintained for longer than recommended. Our research group has conducted a series of in-depth qualitative analyses that have deepened our understanding of the impact of organizational culture in long-term care facilities on the use of psychotropic medications.The COVID-19 pandemic presents many medical and social issues for older people. Presented here is a range of information arising from related areas that have impact upon the safety and efficacy of drug therapy in the context of COVID-19. Issues include pharmacy practice, clinical therapeutics, and possible new treatments for the virus. More information will be published in coming issues of The Senior Care Pharmacist.Now, more than ever, older people need pharmacists to protect them from medication-related problems inherent to psychotropic drugs. It is clear that, because of their specific training and technical knowledge in the area of pharmacotherapy, pharmacists have a logical place in any multidisciplinary context where drug treatment is prescribedâ-"and always will be.Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide and a leading cause of death worldwide. Its incidence continues to increase in the US due to hepatitis C infection and nonalcoholic steatohepatitis. Liver transplantation and resection remain the best therapeutic options for a cure, but these are limited by the shortage of available organs for transplantation, diagnosis at an advanced stage, and underlying chronic liver disease found in most patients with HCC. A-1331852 supplier Immune checkpoint inhibitors (ICIs) have been shown to be an evolving novel treatment option in certain advanced solid tumors and have been recently approved for inoperable, advanced and metastatic HCC. Unfortunately, a large cohort of patients with HCC fail to respond to immunotherapy. In this review, we discuss the ICIs currently approved for HCC treatment and their various mechanisms of action. We will highlight the current understanding of the mechanism of resistance and limitations to ICIs. Finally, we will describe emerging biomarkers of response to ICIs and address future direction on overcoming resistance to immune checkpoint therapy.BACKGROUND Rates of common mental health problems (depression/anxiety) rise sharply in adolescence and peak in young adulthood, often coinciding with the transition to parenthood. Little is known regarding the persistence of common mental health problems from adolescence to the perinatal period in both mothers and fathers. METHODS A total of 393 mothers (686 pregnancies) and 257 fathers (357 pregnancies) from the intergenerational Australian Temperament Project Generation 3 Study completed self-report assessments of depression and anxiety in adolescence (ages 13-14, 15-16, 17-18 years) and young adulthood (ages 19-20, 23-24, 27-28 years). The Edinburgh Postnatal Depression Scale was used to assess depressive symptoms at 32 weeks pregnancy and 12 months postpartum in mothers, and at 12 months postpartum in fathers. RESULTS Most pregnancies (81%) in which mothers reported perinatal depression were preceded by a history of mental health problems in adolescence or young adulthood. Similarly, most pregnancies (83%) in which fathers reported postnatal depression were preceded by a preconception history of mental health problems.